


# Imaging in Endocrinology

PAOLO POZZILLI, ANDREA LENZI, BART L. CLARKE, WILLIAM F. YOUNG JR



WILEY Blackwell



# Imaging in Endocrinology

## Paolo Pozzilli MD

Professor of Endocrinology  
Chair, Department of Endocrinology and Diabetes  
University Campus Bio-Medico  
Rome, Italy;  
Professor of Diabetes Research  
Centre of Diabetes  
The Blizzard Institute  
St. Bartholomew's and the London School of Medicine  
Queen Mary University of London  
London, UK

## Andrea Lenzi MD

Professor of Endocrinology  
Chair, Section of Medical Pathophysiology, Food Science, and Endocrinology  
Department of Experimental Medicine  
Sapienza University of Rome  
Policlinico Umberto I  
Rome, Italy

## Bart L Clarke MD

Associate Professor of Medicine  
Division of Endocrinology, Diabetes, Metabolism, and Nutrition  
Department of Internal Medicine  
Mayo Clinic College of Medicine  
Rochester, MN, USA

## William F Young Jr MD, MSc

Chair, Division of Endocrinology, Diabetes, Metabolism, and Nutrition  
Tyson Family Endocrinology Clinical Professor  
Professor of Medicine  
Mayo Clinic College of Medicine  
Rochester, MN, USA

WILEY Blackwell

This edition first published 2014 © 2014 by John Wiley & Sons, Ltd

*Registered office:* John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex,  
PO19 8SQ, UK

*Editorial offices:* 9600 Garsington Road, Oxford, OX4 2DQ, UK  
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK  
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell)

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*

Pozzilli, Paolo, author.

Imaging in endocrinology / Paolo Pozzilli, Andrea Lenzi, Bart L. Clarke, William F. Young Jr.  
p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-65627-3 (cloth : alk. paper) – ISBN 978-1-118-74907-4 (epub) – ISBN 978-1-118-74908-1 – ISBN 978-1-118-74930-2 (emobi) – ISBN 978-1-118-74931-9 (epdf)

I. Lenzi, Andrea, author. II. Clarke, Bart, author. III. Young, William F., Jr., 1951- author. IV. Title.

[DNLM: 1. Endocrine System Diseases--Atlases. 2. Diagnostic Imaging--methods--Atlases. 3. Metabolic Diseases--Atlases. WK 17]

RC649

616.40022'3--dc23

2013029209

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover images: © the authors

Cover designer: Visual Philosophy, Ltd., Oxford

Set in 9/12pt Meridien by Aptara® Inc., New Delhi, India

Printed and bound in Singapore by Markono Print Media Pte Ltd

## Imaging in Endocrinology

## About the Companion Website

This book is accompanied by a companion website:  
[www.wiley.com/go/Pozzilli/endocrinemetabolicdisease](http://www.wiley.com/go/Pozzilli/endocrinemetabolicdisease)

The website includes:

- Powerpoints of all figures from the book for downloading



# Preface

No medical discipline requires such a precise phenotypic classification and careful consideration of the “image” as does endocrinology. Indeed, it is from “observation” that the endocrinologist extrapolates the elements upon which he or she bases clinical reasoning in the identification of a medical condition.

This atlas aims to be a valuable guide in endocrine diagnosis – suitable for both specialists and physicians in training, as well as physicians in other disciplines with an interest in endocrine disorders. Using the image as a unifying theme, we address the most salient themes of the science of endocrinology – including thyroid, pituitary, adrenal, endocrine pancreas, bone and mineral metabolism, and gonads. Each section provides iconographic support for the pathologies examined.

The universal character of this atlas guarantees a high standard of quality. The work was carried out in both Italy and the USA and has the added benefit of combining the

rigor and scientific integrity belonging to the cradle of modern endocrinology (Rome) and the clinical resources of a major quaternary endocrine referral center (Mayo Clinic).

We would like to express our gratitude to all those who collaborated on this project. Their passion and enthusiasm toward the completion of this work has been exceptional. Without their hard work and dedication, this publication would have not seen the light.

We would also like to thank Wiley and its editors, who have demonstrated, once again, the high level of professionalism and special attention to detail needed to successfully bring to fruition this type of publication. We hope you enjoy consulting the Atlas.

*Paolo Pozzilli, Andrea Lenzi, Bart L Clarke  
and William F Young Jr  
July 2013*

# Collaborators

## **Giusy Beretta**

(collaborator for Thyroid and Pancreas chapters)  
Senior Investigator  
Dept of Endocrinology and Diabetes  
University Campus Bio-Medico  
Rome, Italy

## **Daniele Gianfrilli**

(collaborator for Gonads and Mucocutaneous Manifestations of Endocrine Disorders chapters)  
Senior Investigator in Endocrinology  
Dept of Experimental Medicine  
Section of Medical Pathophysiology, Food Science, and Endocrinology  
Sapienza University of Rome  
Rome, Italy

## **Elisa Giannetta**

(collaborator for Gonads and Mucocutaneous Manifestations of Endocrine Disorders chapters)  
Senior Investigator in Endocrinology  
Dept of Experimental Medicine  
Section of Medical Pathophysiology, Food Science, and Endocrinology  
Sapienza University of Rome  
Rome, Italy

## **Andrea M. Isidori**

(collaborator for Gonads and Mucocutaneous Manifestations of Endocrine Disorders chapters)  
Assistant Professor of Endocrinology  
Dept of Experimental Medicine  
Section of Medical Pathophysiology, Food Science, and Endocrinology  
Sapienza University of Rome  
Rome, Italy

## **Angelo Lauria**

(collaborator for Thyroid and Pancreas chapters)  
Senior Investigator  
Dept of Endocrinology and Diabetes  
University Campus Bio-Medico  
Rome, Italy

## **Andrea Palermo**

(collaborator for Thyroid and Pancreas chapters)  
Senior Investigator  
Dept of Endocrinology and Diabetes  
University Campus Bio-Medico  
Rome, Italy

## **Alberto Signore**

(collaborator for Thyroid and Pancreas chapters)  
Professor, Dept of Nuclear Medicine  
Sapienza University II Medical Faculty  
Rome, Italy; and  
Dept of Nuclear Medicine  
University of Groningen,  
The Netherlands

# Contents

About the Companion Website, xii

Preface, xiii

Collaborators, xiv

## Chapter 1 Thyroid, 1

### Hashimoto's thyroiditis

(chronic autoimmune thyroiditis), 1

Definition and epidemiology, 1

Etiology and pathogenesis, 1

Signs and symptoms, 1

Diagnosis, 1

Treatment, 1

Illustrations (Figs 1.1–1.4), 2–3

### Graves' disease (Basedow's disease), 4

Definition and epidemiology, 4

Etiology and pathogenesis, 4

Signs and symptoms, 4

Diagnosis, 4

Treatment, 4

Illustrations (Figs 1.5 & 1.6), 5

### Subacute thyroiditis

(de Quervain's thyroiditis), 6

Definition and epidemiology, 6

Etiology and pathogenesis, 6

Signs and symptoms, 6

Diagnosis, 6

Treatment, 6

Illustration (Fig. 1.7), 7

### Benign thyroid nodules, 8

Definition and epidemiology, 8

Etiology and pathogenesis, 8

Signs and symptoms, 8

Diagnosis, 8

Treatment, 8

Illustrations (Figs 1.8–1.11), 9–10

### Thyroid cancer, 11

Definition and epidemiology, 11

Etiology and pathogenesis, 11

Signs and symptoms, 11

Diagnosis, 11

Treatment, 12

Illustrations (Figs 1.12–1.25), 13–21

## Chapter 2 Pituitary Gland, 22

### Craniopharyngioma, 22

Definition, 22

Etiology, 22

Signs and symptoms, 22

Diagnosis, 22

Treatment, 22

Illustrations (Figs 2.1–2.3), 23

### Hypothalamic dysgerminoma, 24

Definition, 24

Etiology, 24

Signs and symptoms, 24

Diagnosis, 24

Treatment, 24

Illustrations (Figs 2.4 & 2.5), 24

### Growth hormone-secreting pituitary tumor, 25

Definition, 25

Etiology, 25

Signs and symptoms, 25

Diagnosis, 25

Treatment, 25

Illustrations (Figs 2.6–2.10), 25–26

### Prolactin-secreting pituitary tumor, 27

Definition, 27

Etiology, 27

Signs and symptoms, 27

Diagnosis, 27

Treatment, 27

Illustrations (Figs 2.11–2.13), 27–28



**Corticotropin-secreting pituitary tumor (Cushing syndrome), 29**

Definition, 29  
Etiology, 29  
Signs and symptoms, 29  
Diagnosis, 29  
Treatment, 29  
Illustrations (Figs 2.14–2.16), 30

**Nelson syndrome, 31**

Definition, 31  
Etiology, 31  
Signs and symptoms, 31  
Diagnosis, 31  
Treatment, 31  
Illustrations (Figs 2.17–2.20), 31–32

**Clinically nonfunctioning pituitary tumors, 33**

Definition, 33  
Etiology, 33  
Signs and symptoms, 33  
Diagnosis, 33  
Treatment, 33  
Illustrations (Figs 2.21–2.23), 34

**Primary pituitary carcinoma, 35**

Definition, 35  
Etiology, 35  
Signs and symptoms, 35  
Diagnosis, 35  
Treatment, 35  
Illustrations (Figs 2.24–2.27), 36

**Pituitary cyst, 37**

Definition, 37  
Etiology, 37  
Signs and symptoms, 37  
Diagnosis, 37  
Treatment, 37  
Illustrations (Figs 2.28–2.31), 38–39

**Nontumorous lesions of the pituitary gland and pituitary stalk, 40**

Definition, 40  
Etiology, 40  
Signs and symptoms, 40  
Diagnosis, 40  
Treatment, 40  
Illustrations (Figs 2.32–2.34), 41–42

**Pituitary apoplexy, 43**

Definition, 43  
Etiology, 43  
Signs and symptoms, 43

Diagnosis, 43  
Treatment, 43  
Illustrations (Figs 2.35–2.37), 43–44

**Tumors metastatic to the pituitary, 45**

Definition, 45  
Etiology, 45  
Signs and symptoms, 45  
Diagnosis, 45  
Treatment, 45  
Illustrations (Figs 2.38 & 2.39), 46

**Chapter 3 Adrenal Gland, 47**

**Adrenal incidentaloma, 47**

Definition, 47  
Etiology, 47  
Signs and symptoms, 47  
Diagnosis, 47  
Treatment, 47  
Illustrations (Figs 3.1–3.4), 48–49

**Adrenocortical carcinoma, 50**

Definition, 50  
Etiology, 50  
Signs and symptoms, 50  
Diagnosis, 50  
Treatment, 50  
Illustrations (Figs 3.5–3.8), 51

**Adrenal-dependent Cushing syndrome, 52**

Definition, 52  
Etiology, 52  
Signs and symptoms, 52  
Diagnosis, 52  
Treatment, 52  
Illustrations (Figs 3.9–3.14), 53–54

**Classic congenital adrenal hyperplasia, 55**

Definition, 55  
Etiology, 55  
Signs and symptoms, 55  
Diagnosis, 55  
Treatment, 56  
Illustrations (Figs 3.15 & 3.16), 56–57

**Primary aldosteronism, 58**

Definition, 58  
Etiology, 58  
Signs and symptoms, 58  
Diagnosis, 58  
Treatment, 58  
Illustrations (Figs 3.17 & 3.18), 59–60

**Adrenal venous sampling, 61**

Definition, 61  
 Background, 61  
 Procedure and keys to successful AVS, 61  
 Interpretation of AVS, 61  
 Illustrations (Figs 3.19 & 3.20), 62

**Primary adrenal failure (Addison's disease), 63**

Definition, 63  
 Etiology, 63  
 Signs and symptoms, 63  
 Diagnosis, 63  
 Treatment, 63  
 Illustrations (Figs 3.21–3.23), 64

**Pheochromocytoma, 65**

Definition, 65  
 Etiology, 65  
 Signs and symptoms, 65  
 Diagnosis, 65  
 Treatment, 65  
 Illustrations (Figs 3.24–3.30), 66–67

**Paraganglioma, 68**

Definition, 68  
 Etiology, 68  
 Signs and symptoms, 68  
 Diagnosis, 68  
 Treatment, 68  
 Illustrations (Figs 3.31–3.35), 69–71

**Adrenal infarction, 72**

Definition, 72  
 Etiology, 72  
 Signs and symptoms, 72  
 Diagnosis, 72  
 Treatment, 72  
 Illustrations (Figs 3.36 & 3.37), 73

**Tumors metastatic to the adrenal glands, 74**

Definition, 74  
 Etiology, 74  
 Signs and symptoms, 74  
 Diagnosis, 74  
 Treatment, 74  
 Illustrations (Figs 3.38 & 3.39), 75

**Chapter 4 Pancreas, 76****Diabetes, 76**

*Diabetes and cardiovascular disease, 76*  
 Definition and pathogenesis, 76  
 Etiology, 76

Signs and symptoms, 76

Diagnosis, 77

Treatment, 77

Illustrations (Figs 4.1–4.5), 77–79

***Skin diseases associated with diabetes, 80***

Definition, 80

Etiology, 80

Signs and symptoms, 80

Diagnosis, 80

Treatment, 80

Illustrations (Figs 4.6 & 4.7), 80–81

***Diabetic foot, 81***

Definition, 81

Pathophysiology and etiology, 81

Signs and symptoms, 81

Diagnosis, 82

Treatment, 82

Illustrations (Figs 4.8–4.22), 82–86

***Diabetic neuropathy, 87***

Definition, 87

Etiology, 87

Diagnosis, 87

Treatment, 87

Illustrations (Figs 4.23 & 4.24), 88

***Diabetic nephropathy, 89***

Definition, 89

Etiology, 89

Signs and symptoms, 89

Diagnosis, 89

Prevention and treatment, 90

Illustrations (Figs 4.25–4.28), 90–91

***Diabetic retinopathy, 92***

Definition, 92

Etiology, 92

Signs and symptoms, 92

Diagnosis, 92

Treatment, 92

Illustrations (Figs 4.29–4.38), 93–94

**Insulinoma, 95**

Definition, 95

Etiology, 95

Signs and symptoms, 95

Diagnosis, 95

Treatment, 95

Illustrations (Figs 4.39–4.42), 95–96

**Acute pancreatitis, 96**

Definition, 96

Etiology, 96

Signs and symptoms, 96

Diagnosis, 96

Treatment, 97

Illustrations (Figs 4.43–4.45), 97

**Chronic pancreatitis, 98**

- Definition, 98
- Etiology, 98
- Signs and symptoms, 98
- Diagnosis, 98
- Treatment, 98
- Illustrations (Figs 4.46–4.48), 98–99

**Chapter 5 Bone and Mineral Metabolism, 100**

**Osteoporosis, 100**

- Definition, 100
- Etiology, 100
- Signs and symptoms, 101
- Diagnosis, 101
- Treatment, 101
- Illustrations (Figs 5.1–5.5), 101–102

**Primary hyperparathyroidism, 103**

- Definition, 103
- Etiology, 103
- Signs and symptoms, 103
- Diagnosis, 103
- Treatment, 104
- Illustrations (Figs 5.6–5.16), 105–108

**Hypoparathyroidism, 108**

- Definition, 108
- Etiology, 108
- Signs and symptoms, 109
- Diagnosis, 109
- Treatment, 110
- Illustrations (Figs 5.17–5.19), 110

**Pseudohypoparathyroidism, 111**

- Definition, 111
- Etiology, 111
- Signs and symptoms, 111
- Diagnosis, 111
- Treatment, 112
- Illustrations (Figs 5.20 & 5.21), 112

**Paget's disease of bone, 113**

- Definition, 113
- Etiology, 113
- Signs and symptoms, 113
- Diagnosis, 114
- Treatment, 114
- Illustrations (Figs 5.22–5.28), 114–116

**Osteomalacia, 116**

- Definition, 116

- Etiology, 116
- Signs and symptoms, 117
- Diagnosis, 118
- Treatment, 118
- Illustrations (Figs 5.29–5.35), 119–120

**Chronic kidney disease, 121**

- Definition, 121
- Etiology, 121
- Signs and symptoms, 121
- Diagnosis, 121
- Treatment, 122
- Illustrations (Figs 5.36–5.40), 123–124

**Fibrous dysplasia, 125**

- Definition, 125
- Etiology, 125
- Signs and symptoms, 125
- Diagnosis, 126
- Treatment, 126
- Illustrations (Figs 5.41–5.47), 127–128

**Selected sclerosing bone disorders, 129**

- Definition, 129
- Osteopetrosis, 129***
- Etiology, 129
- Signs and symptoms, 129
- Diagnosis, 130
- Treatment, 130
- Illustrations (Figs 5.48–5.51), 131

***Pycnodysostosis, 132***

- Etiology, 132
- Signs and symptoms, 132
- Diagnosis, 132
- Treatment, 132
- Illustrations (Figs 5.52–5.54), 133

***Melorheostosis, 134***

- Etiology, 134
- Signs and symptoms, 134
- Diagnosis, 134
- Treatment, 134
- Illustrations (Figs 5.55 & 5.56), 134

***Progressive diaphyseal dysplasia***

***(Camurati–Engelmann disease), 135***

- Etiology, 135
- Signs and symptoms, 135
- Diagnosis, 135
- Treatment, 135
- Illustration (Fig. 5.57), 136

***Hepatitis C-associated osteosclerosis, 136***

- Etiology, 136
- Signs and symptoms, 136
- Diagnosis, 136

Treatment, 136

Illustrations (Figs 5.58–5.60), 137

***Familial high bone mass phenotype due to Lrp5 mutation, 138***

Etiology, 138

Signs and symptoms, 138

Diagnosis, 138

Treatment, 138

Illustrations (Figs 5.61 & 5.62), 138

***Erdheim–Chester disease, 139***

Etiology, 139

Signs and symptoms, 139

Diagnosis, 139

Treatment, 139

Illustrations (Figs 5.63–5.65), 140

***Skeletal fluorosis, 141***

Etiology, 141

Signs and symptoms, 141

Diagnosis, 141

Treatment, 141

Illustrations (Figs 5.66 & 5.67), 142

**Tumoral calcinosis, 143**

Definition, 143

Etiology, 143

Signs and symptoms, 143

Diagnosis, 144

Treatment, 144

Illustrations (Figs 5.68 & 5.69), 144–145

**Osteogenesis imperfecta, 145**

Definition, 145

Etiology, 145

Signs and symptoms, 145

Diagnosis, 147

Treatment, 147

Illustrations (Figs 5.70–5.77), 148–149

**Other skeletal disorders, 150**

***Osteoporosis–pseudoglioma (OPPG) syndrome, 150***

Definition, 150

Etiology, 150

Signs and symptoms, 150

Diagnosis, 150

Treatment, 150

Illustrations (Figs 5.78–5.81), 150–151

***Hajdu–Cheney syndrome (hereditary osteodysplasia with acro-osteolysis), 152***

Definition, 152

Etiology, 152

Signs and symptoms, 152

Diagnosis, 152

Treatment, 152

Illustration (Fig. 5.82), 152

***Hypophosphatasia, 153***

Definition, 153

Etiology, 153

Signs and symptoms, 153

Diagnosis, 153

Treatment, 154

Illustrations (Figs 5.83 & 5.84), 154

## Chapter 6 Gonads, 155

### Male gonads, 155

***Testes, 155***

Definition, 155

Function, 155

Tests, 155

Treatment, 156

Illustrations (Figs 6.1–6.4), 156–157

***Testicular cancer, 158***

Definition and epidemiology, 158

Etiology, 158

Signs and symptoms, 158

Diagnosis, 158

Treatment, 159

Illustrations (Figs 6.5–6.8), 159–162

***Cryptorchidism, 163***

Definition, 163

Etiology, 163

Signs and symptoms, 163

Diagnosis, 163

Treatment, 163

Illustrations (Figs 6.9 & 6.10), 164–165

***Gynecomastia, 166***

Definition, 166

Etiology, 166

Diagnosis, 166

Treatment, 167

Illustrations (Figs 6.11–6.13), 167–168

***Klinefelter syndrome, 169***

Definition, 169

Etiology, 169

Signs and symptoms, 169

Diagnosis, 169

Treatment, 169

Illustrations (Figs 6.14–6.16), 170–172

***Male infertility, 173***

Definition, 173

Etiology, 173

Diagnosis, 173

Treatment, 174

Illustrations (Figs 6.17–6.19), 174

***Varicocele, 175***

Definition, 175



Etiology, 175  
 Signs and symptoms, 175  
 Diagnosis, 175  
 Treatment, 175  
 Illustrations (Figs 6.20–6.23), 176–177

## **Female gonads, 178**

### ***Ovary, 178***

Definition, 178  
 Function, 178  
 Treatment, 179  
 Illustrations (Figs 6.24 & 6.25), 179–180

### ***Ovarian cancer, 181***

Definition and epidemiology, 181  
 Etiology, 181  
 Signs and symptoms, 181  
 Diagnosis, 181  
 Treatment, 182  
 Illustrations (Figs 6.26–6.30), 183–187

### ***Ovarian cysts, 188***

Definition, 188  
 Etiology, 188  
 Signs and symptoms, 188  
 Diagnosis, 188  
 Treatment, 189  
 Illustrations (Figs 6.31–6.35), 189–193

### ***Amenorrhea, 194***

Definition, 194  
 Etiology, 194  
 Signs and symptoms, 194  
 Diagnosis, 194  
 Treatment, 195  
 Illustrations (Figs 6.36–6.39), 195–197

### ***Hyperandrogenism in women, 198***

Definition and etiology, 198  
 Signs and symptoms, 198  
 Diagnosis, 198  
 Treatment, 198  
 Illustrations (Figs 6.40–6.42), 199–200

### ***Polycystic ovary syndrome, 201***

Definition, 201  
 Etiology, 201  
 Signs and symptoms, 201  
 Diagnosis, 201  
 Treatment, 201  
 Illustrations (Figs 6.43–6.45), 202–203

### ***Turner syndrome, 204***

Definition, 204  
 Etiology, 204  
 Signs and symptoms, 204  
 Diagnosis, 204  
 Treatment, 204  
 Illustrations (Fig. 6.46), 205

## **Chapter 7 Mucocutaneous Manifestations of Endocrine Disorders, 206**

### **Acanthosis nigricans, 206**

Definition, 206  
 Etiology, 206  
 Signs and symptoms, 206  
 Diagnosis, 207  
 Treatment, 207  
 Illustrations (Figs 7.1 & 7.2), 207–208

### **Acne, 209**

Definition, 209  
 Etiology, 209  
 Signs and symptoms, 209  
 Diagnosis, 209  
 Treatment, 209  
 Illustrations (Figs 7.3 & 7.4), 210

### **Alopecia, 211**

Definition, 211  
 Etiology, 211  
 Signs and symptoms, 211  
 Diagnosis, 211  
 Treatment, 212  
 Illustrations (Figs 7.5 & 7.6), 213–214

### **Café-au-lait macules, 215**

Definition, 215  
 Etiology, 215  
 Signs and symptoms, 215  
 Diagnosis, 215  
 Treatment, 216  
 Illustration (Fig. 7.7), 216

### **Mucocutaneous neuromas, 217**

Definition, 217  
 Etiology, 217  
 Signs and symptoms, 217  
 Diagnosis, 217  
 Treatment, 217  
 Illustrations (Figs 7.8 & 7.9), 218

### **Necrolytic migratory erythema, 219**

Definition, 219  
 Etiology, 219  
 Signs and symptoms, 219  
 Diagnosis, 219  
 Treatment, 219  
 Illustration (Fig. 7.10), 219

### **Neurofibromas, 220**

Definition, 220



Etiology, 220  
Signs and symptoms, 220  
Diagnosis, 220  
Treatment, 220  
Illustrations (Figs 7.11–7.13), 221–222

**Vitiligo, 223**

Definition, 223

Etiology, 223  
Signs and symptoms, 223  
Diagnosis, 223  
Treatment, 223  
Illustrations (Figs 7.14–7.16), 224–225

Index, 227

## Hashimoto's thyroiditis (chronic autoimmune thyroiditis)

### Definition and epidemiology

Hashimoto's thyroiditis (HT), or chronic lymphocytic thyroiditis, is an autoimmune disease in which the thyroid gland is attacked by a variety of cell and antibody-mediated immune processes. The name "Hashimoto's thyroiditis" is derived from the 1912 original report by Hashimoto describing patients with both goiter and intense lymphocytic infiltration of the thyroid (Figs 1.1 & 1.2) as "struma lymphomatosa."

Hashimoto's thyroiditis is the most common cause of primary hypothyroidism in iodine-sufficient areas of the world; it is among the most common causes of nonendemic goiter. On average 1.0–1.5/1000 people suffer from this disease. It occurs far more often in women than in men (incidence of 10 : 1 to 20 : 1, respectively), and it is most prevalent between 45 and 65 years of age. Occurrence in children is also uncommon, especially in populations where iodine is not a dietary scarcity.

### Etiology and pathogenesis

Autoantibodies may be present against thyroid peroxidase, thyroglobulin, and thyroid-stimulating hormone (TSH) receptors, although a small percentage of patients may have none of these antibodies present. Antibody-dependent cell-mediated cytotoxicity is a substantial factor behind the apoptotic fallout of HT. Activation of cytotoxic T lymphocytes (CD8<sup>+</sup> T cells) in response to cell-mediated immune response affected by helper T lymphocytes (CD4<sup>+</sup> T cells) is central to thyrocyte destruction. Recruitment of macrophages is another effect of helper T-lymphocyte activation, with Th1-axis lymphocytes producing inflammatory

cytokines within the thyroid tissue to further macrophage activation and migration into the thyroid gland for a direct effect. Infection, stress, sex steroids, pregnancy, iodine intake, and radiation exposure are known possible precipitating factors for HT. Fetal microchimerism within the maternal thyroid is also a possibility.

### Signs and symptoms

Hashimoto's thyroiditis very often results in hypothyroidism with bouts of hyperthyroidism. Symptoms of HT include weight gain, depression, mania, sensitivity to heat and cold, paresthesia, fatigue, panic attacks, bradycardia, tachycardia, high cholesterol, reactive hypoglycemia, constipation, migraine, muscle weakness, cramps, memory loss, infertility, hair loss, and myxedematous psychosis.

### Diagnosis

#### Laboratory findings

Laboratory tests for HT include:

- Antithyroid peroxidase antibodies (TPOAbs) and thyroglobulin antibodies (TgAbs)
- TSH, free thyroxine (FT<sub>4</sub>)
- Total cholesterol, high density lipoprotein (HDL), and triglycerides

#### Imaging tests


Imaging tests for HT include:

- Neck ultrasound (Fig. 1.3)
- Computed tomography (CT) scan (rare)
- <sup>99m</sup>TcO<sub>4</sub> thyroid scintigraphy (Fig. 1.4)


### Treatment

In patients with primary hypothyroidism, the main treatment is levothyroxine.

**Illustrations (Figs 1.1–1.4)**




**Figure 1.1** Cytology of thyroiditis. This figure shows rare and normal thyrocytes associated with numerous lymphocytes (Papanicolaou, 10 ×).




**Figure 1.2** Histology of thyroiditis. Hashimoto thyroiditis is characterized by Hürthle cells associated with follicular lymphoid structures (HE, 10 ×).






(a)

**Figure 1.3** A 46-year-old woman with a recent episode of cervical tenderness and a familiar history of thyroid disease. The patient complained of fatigue and reported a weight gain of about 10 kg in the last 2 months. (a) Thyroid ultrasound – cross section. This ultrasound shows a thyroid with a slight increase in volume, globular shape, and homogeneous structure, and less echogenic than normal. (b) Thyroid




(b)

ultrasound – longitudinal section. This ultrasound shows diffuse patchy hypoechoic lesions throughout the gland. This sonographic appearance is called a "leopard skin" pattern and is seen in lymphocytic infiltration of the thyroid in Hashimoto's thyroiditis. The hypoechoic lesions within the thyroid are areas of lymphocytic infiltration of the thyroid tissue. C, carotid artery; H, hypoechoic lesions; P, thyroid parenchyma; T, trachea.



(a)



(b)

**Figure 1.4** The same patient as in Fig. 1.3:  $^{99m}\text{TcO}_4$  thyroid scintigraphy with iodine uptake curve. Iodine uptake was 2% at 4 hours (a) and 2% at 24 hours (b). The scan showed no uptake in the thyroid bed. The free triiodothyronine ( $\text{FT}_3$ ) and free thyroxine ( $\text{FT}_4$ ) levels were low with elevated thyroid stimulating hormone (TSH) and antibodies against thyroperoxidase (TPOAb) values. The patient started levothyroxine treatment.